Metabolic checkpoints and novel approaches for immunotherapy against cancer.
Metabolic checkpoints and novel approaches for immunotherapy against cancer.
复制标题
代谢检查点和癌症免疫治疗的新方法
DOI：
10.1002/ijc.33781
复制
发表时间：
2022-01-15
影响因子：
6.4
通讯作者：
Chen, Zhinan
中科院分区：
文献类型：
--
作者：
Li, Yiming;Tang, Juan;Jiang, Jianli;Chen, Zhinan
虽然免疫疗法在征服癌症方面取得了前所未有的成功，但大多数患者对免疫疗法产生了原发性或获得性抗性，这在很大程度上是由于肿瘤微环境中复杂的代谢网络。微环境代谢网络由一组代谢检查点编织而成，越来越多的证据表明这些代谢检查点协调了抗肿瘤免疫和免疫治疗。代谢检查点可以调节T细胞的发育、分化和功能，协调肿瘤细胞和浸润性T细胞之间的代谢竞争，并响应施加在浸润性T细胞上的代谢应激。此外，代谢检查点和途径可以调节免疫检查点受体和配体的表达谱，反之亦然。因此，针对代谢检查点的干预措施可能与免疫疗法协同作用，并且更有希望的方法来重新编程代谢环境。本文综述了近年来代谢检查点的研究进展，讨论了代谢检查点如何调节抗肿瘤免疫，以及在联合治疗中调控代谢检查点的可能途径。全面、客观地了解代谢检查点有助于抗肿瘤免疫治疗新方法的研究和开发。
While immunotherapy has achieved unprecedented success in conquering cancer, the majority of patients develop primary or acquired resistance to immunotherapy, largely in part due to the complicated metabolic networks in the tumor microenvironment. The microenvironmental metabolic networks are woven by a set of metabolic checkpoints, and accumulating evidence indicates that these metabolic checkpoints orchestrate antitumor immunity and immunotherapy. Metabolic checkpoints can regulate T cell development, differentiation and function, orchestrate metabolic competition between tumor cells and infiltrating T cells, and respond to the metabolic stress imposed on the infiltrating T cells. Furthermore, metabolic checkpoints and pathways can modulate the expression profiles of immune checkpoint receptors and ligands and vice versa. Therefore, repurposing interventions targeting metabolic checkpoints might synergize with immunotherapy, and promising approaches to reprogram the metabolic environment are much more warranted. In this review, we summarize recent researches on the metabolic checkpoints and discuss how these metabolic checkpoints regulate antitumor immunity and the promising approaches to modulate these metabolic checkpoints in the combination therapy. A comprehensive and objective understanding of the metabolic checkpoints might help the research and development of novel approaches to antitumor immunotherapy.
登录
查看更多内容
影响因子：
29
作者：
Cascone T;McKenzie JA;Mbofung RM;Punt S;Wang Z;Xu C;Williams LJ;Wang Z;Bristow CA;Carugo A;Peoples MD;Li L;Karpinets T;Huang L;Malu S;Creasy C;Leahey SE;Chen J;Chen Y;Pelicano H;Bernatchez C;Gopal YNV;Heffernan TP;Hu J;Wang J;Amaria RN;Garraway LA;Huang P;Yang P;Wistuba II;Woodman SE;Roszik J;Davis RE;Davies MA;Heymach JV;Hwu P;Peng W
通讯作者：
Peng W
影响因子：
30.5
作者：
Chang CH;Pearce EL
通讯作者：
Pearce EL
影响因子：
64.8
作者：
Cronin SJF;Seehus C;Weidinger A;Talbot S;Reissig S;Seifert M;Pierson Y;McNeill E;Longhi MS;Turnes BL;Kreslavsky T;Kogler M;Hoffmann D;Ticevic M;da Luz Scheffer D;Tortola L;Cikes D;Jais A;Rangachari M;Rao S;Paolino M;Novatchkova M;Aichinger M;Barrett L;Latremoliere A;Wirnsberger G;Lametschwandtner G;Busslinger M;Zicha S;Latini A;Robson SC;Waisman A;Andrews N;Costigan M;Channon KM;Weiss G;Kozlov AV;Tebbe M;Johnsson K;Woolf CJ;Penninger JM
通讯作者：
Penninger JM
影响因子：
64.5
作者：
Chang CH;Curtis JD;Maggi LB Jr;Faubert B;Villarino AV;O'Sullivan D;Huang SC;van der Windt GJ;Blagih J;Qiu J;Weber JD;Pearce EJ;Jones RG;Pearce EL
通讯作者：
Pearce EL
影响因子：
64.5
作者：
Buck MD;Sowell RT;Kaech SM;Pearce EL
通讯作者：
Pearce EL